Abstract: BACKGROUND: Clinical observations are suggesting accelerated granulation tissue formation in traumatic wounds treated with vacuum-assisted closure (VAC). Aim of this study was to determine the impact of VAC therapy versus alternative Epigard application on local inflammation and neovascularization in traumatic soft tissue wounds. METHODS: Thirty-two patients with traumatic wounds requiring temporary coverage (VAC n = 16; Epigard n = 16) were included. At each change of dressing, samples of wound fluid and serum were collected (n = 80). The cytokines interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), and fibroblast growth factor-2 were measured by ELISA. Wound biopsies were examined histologically for inflammatory cells and degree of neovascularization present. RESULTS: All cytokines were found to be elevated in wound fluids during both VAC and Epigard treatment, whereas serum concentrations were negligible or not detectable. In wound fluids, significantly higher IL-8 (p < 0.001) and VEGF (p < 0.05) levels were detected during VAC therapy. Furthermore, histologic examination revealed increased neovascularization (p < 0.05) illustrated by CD31 and von Willebrand factor immunohistochemistry in wound biopsies of VAC treatment. In addition, there was an accumulation of neutrophils as well as an augmented expression of VEGF (p < 0.005) in VAC wound biopsies. CONCLUSION: This study suggests that VAC therapy of traumatic wounds leads to increased local IL-8 and VEGF concentrations, which may trigger accumulation of neutrophils and angiogenesis and thus, accelerate neovascularization. 
Introduction
The management of traumatic wounds remains a major challenge in surgery. A variety of methods of temporary wound closure have been described and used in the past. Among current standards is wound coverage by Epigard™ (Biovision GmbH, Ilmenau, Germany) or by Vacuum-Assisted Closure (VAC™, Kinetic Concepts, Inc., San Antonio, TX, USA) (Figs.
1A and B).
Epigard™ is a two-layer, non-medicated wound dressing which approximates the function of human skin (Fig. 1A) . 1 The superficial Teflon layer is permeable to air, however, prevents the penetration by bacteria and fluids from the outside. The lower layer is made from polyurethane. It is adhesive to the wound exudates and wound ground. Thus, removal of the Epigard™ produces mechanical debridement of the wound. The VAC™ therapy is a temporary protection of soft tissue defects by polyurethane foam which is sealed with a transparent adhesive drape (Fig. 1B) . A negative topical pressure within the wound is then generated using a vacuum pump. 2 VAC™ therapy has been described to be beneficial for the wound management in a variety of clinical traumatic and non traumatic soft tissue defects. 2 This corroborates our clinical observation of improved wound healing of traumatic wounds after VAC™ therapy compared with application of alternative wound dressings e.g.
Epigard™. It has been shown that VAC™ therapy, on the one hand, optimizes micro perfusion and blood flow, increases the partial oxygen pressure within the tissue and reduces bacterial colonialization. 2 The cyclical application of sub-atmospheric pressure, on the other hand, alters the cytoskeleton of the cells in the wound bed triggering a cascade of intracellular signals that increases the rate of cell division and subsequent formation of granulation tissue. 2 However, the exact mechanisms leading to this improved wound healing remain largely unknown.
During each of the three phases of wound healing, inflammation, proliferation and scar formation, local cellular and circulating humoral components play an important role. [3] [4] [5] [6] [7] Among the latter, interleukin (IL)-6 has been described as a pro-and anti-inflammatory mediator. 8 It is a potent inducer of B-cell differentiation and immunoglobulin synthesis as well as acute phase protein expression by hepatocytes. In local trauma, increased IL-6 levels have been demonstrated in wound fluids compared with matched serum. 3 Interleukin(IL)-8 is a leukocyte specific chemoattractant cytokine and seems to play an important role for the recruitment of polymorphonuclear neutrophils (PMN) during the early inflammation phase of wound healing. 9 In addition, IL-8 is also involved in the activation of leukocytes during the tissue repair phases. 10 PMN have recently been shown to express vascular endothelial growth factor (VEGF), and following traumatic brain injury, an early increase in VEGF expression was described within 4 hours post-injury in the traumatized parenchyma associated with invasion of neutrophils granulocytes. 11, 12 VEGF is a growth factor which promotes neovascularization through extension and growth of existing arterial and capillary networks. 13 Macrophages, in addition, infiltrating the wound after PMN, modulate the wound angiogenesis by releasing angiogenic factors such as fibroblast growth factor (FGF)-2 and VEGF. 14 FGF-2, originally called basic FGF, is involved in angiogenesis as well as in granulation tissue formation. 15 Whereas tissue hypoxia has been described as a potent stimulator for expression of VEGF proteins and their receptors by macrophages, FGF proteins are released secondary to cell damage. 9, 16 The von Willebrand Factor (vWF) is synthesised by and stored in endothelial cells. 17 When released, vWF appears to mediate platelet aggregation and adhesion. CD 31 is also expressed in endothelial cells and therefore, immunhistochemistry for CD31 and vWF can be used for illustrating and counting microvessel density in biospies. 16 As clinical observations and own previous investigations 18 are suggesting accelerated granulation tissue formation and wound healing of traumatic soft tissue defects undergoing VAC™ treatment, the aim of this study was to determine the impact of VAC™ therapy versus alternative Epigard™ application on local inflammation in the management of traumatic 6 wounds. Specifically to measure wound cytokine levels of IL-6, IL-8, VEGF and FGF-2 and furthermore to assess for neovascularization in the two treatment groups.
Patients and Methods

Patients and surgical management
A total of 32 patients suffering from traumatic soft tissue injuries requiring temporary wound closure after surgical debridement were prospectively included in the study ( When VAC-therapy was used, the polyurethane foam was cut and fixed to the wound edge using skin staples or sutures. It was then sealed with a transparent adhesive tape and continuous negative topical pressure of 125 mmHg was applied using a vacuum pump. When
Epigard was applied, the dressing was cut and fixed to the wound edge using skin staples or 
Measurement of cytokines in wound fluid and serum samples
The cytokines IL-6, IL-8, VEGF and FGF-2 were analyzed by specific enzyme linked immunosorbent assays (ELISA) using commercially available ELISA kits (R&D Systems, Abingdon, UK).
Histopathology and Immunohistochemistry of wound tissue biopsies
In addition to wound fluid and serum collection, at the first removal of VAC™ or Epigard™ dressing, tissue biopsies and attached foam samples from the center of the wound were collected, fixed in buffered formaldehyde 4% and embedded in paraffin blocks. From each paraffin block 2µm thick slides were cut and stained with Hematoxylin-Eosin (H&E). Due to the typical cytomorphology of PMN and macrophages no special stains were needed for their identification. In order to count neovascularisation, immunohistochemistry for VEGF, vWF and CD31 was performed on paraffin sections of formalin fixed tissues, using a Ventana
Benchmark automated staining system (Ventana Medical Systems, Tucson, Arizona). For antigen retrieval, slides were heated with cell conditioner 1 (standard procedure). Endogenous biotin was blocked with the appropriate kit. Primary polyclonal rabbit antibody against VEGF (Neomarkers Lab Vision, dilution 1:100) was then applied and revealed with the Ventana-Red enhanced detection kit. Slides were counterstained with hematoxylin prior to glass coverslipping. CD31 and vWF immunhistochemistry were performed as described above.
Primary polyclonal rabbit antibody against vWF (Dako A/S, Glostrup, Denmark, dilution 1:1000) and primary monoclonal mouse antibody against CD31 (Dako A/S Glostrup, Denmark, dilution 1:10) were used. 
Results
Cytokines in wound fluid and serum after VAC™ and Epigard™ treatment
A total of 80 wound fluid and serum samples from 32 patients were analyzed and IL-6, IL-8, VEGF and FGF-2 concentrations were measured by ELISA. In 24 patients (VAC™ n = 11, Epigard™ n = 13) definitive wound closure was performed at the first change of dressing and one wound fluid and one serum sample per patient could be examined. Eight patients (VAC™ n = 5, Epigard™ n = 3) underwent one change of dressing before definitive wound closure and two consecutive wound fluid and serum samples were analyzed ( Tables 2 and 3 ).
All cytokines were elevated in wound fluids at each removal of dressing during VAC™ therapy as well as Epigard™ treatment ( Table 4) . On the contrary, serum concentrations were negligible or not detectable during both treatments with VAC™ and Epigard™ ( Table 4) .
No statistically significant change of concentration over time could be detected in wound fluids during both VAC™ and Epigard™ therapy for any of the cytokines measured as assessed by one way repeated measures ANOVA. However, comparisons of patient's mean cytokine concentrations in wound fluids revealed statistically significant higher IL-8 (p<0.001; Table 4 ) and VEGF (p<0.05; Table 4 ) levels during VAC™ therapy compared with Epigard™ application. In contrast, a statistically significant difference between VAC™ and Epigard™ treatment was found neither for IL-6 and FGF-2 concentrations in wound fluids nor for any cytokine measured in serum.
Local accumulation of PMN in wound tissue after VAC™ therapy
Histological examination of wound ground biopsies with attached VAC™ foam showed visible higher accumulation of PMN ( Figs. 2A and B) compared to wound ground biopsies with Epigard™ dressing (Figs. 2E and F) . This is in accordance with the locally increased levels of IL-8 in wound fluids during VAC™ therapy. In both treatment groups spare macrophages were identified.
Increased expression of VEGF and corresponding augmented neovascularization in wound tissue after VAC™ therapy
Wound biopsies treated with VAC™ therapy showed immunohistochemically visible higher expression of VEGF (Fig. 2C ) compared to Epigard™ application (Fig. 2G) , which is corroborated statistically by semiquantitative analysis (p<0.005). VEGF was mostly expressed in cells identified as PMN.
In addition, vWF and CD31 immune staining, which visualizes small vessels, showed a statistical significant increased neovascularisation after VAC™ (33.6  2.9, mean  SEM) therapy (Fig. 2D ) compared to Epigard™ (14.0  3.3) treatment (p<0.05) (Fig. 2H) .
Clinical outcome
Clinical outcome parameters are presented in Tables 2 and 3 
Discussion
Although in clinical settings improved and accelerated granulation tissue formation and wound healing has been attributed to VAC™ therapy compared to alternative wound dressings such as Epigard™, the exact underlying mechanisms remain largely unknown.
Experimental studies have previously shown that mechanical stress can induce tissue responses including cytokine release and cell proliferation. [19] [20] [21] [22] Thus, it can be hypothesized that VAC™ therapy may cause mechanically triggered immunomodulation as well as neovascularization and/or angiogenesis, finally leading to improved wound healing. In our present study, therefore, the impact of VAC™ therapy versus alternative Epigard™ application on local inflammation and neovascularization was assessed. The cytokines IL-6, IL-8, VEGF as well as FGF-2 were measured and compared in wound fluids and serum samples of 16 patients treated with VAC™ therapy and 16 patients treated with Epigard™ dressing for traumatic soft tissue injuries requiring temporary wound coverage (Tables 2 and   3 ). Furthermore, wound biopsies were processed for histological examination. The specimens were evaluated as to the presence of PMN, VEGF expression and neovascularization.
In the present study, all the cytokines measured were elevated during the whole study period in wound fluids of both patient groups treated either with VAC™ or Epigard™, whereas serum concentrations remained at constant low levels. These findings are corroborated by a previous report of markedly higher cytokine and growth factor levels in wounds compared with serum in a clinical model of controlled operative plastic surgery trauma, 3 indicating a compartmentalization of the immune response after local soft tissue injuries.
In response to traumatic injuries, IL-6 appears to play an active role in the post injury immune cascade. 23 In local soft tissue injuries e.g. elective surgery, IL-6 serum levels were increased within 90 minutes of skin incision being elevated up to 72 hours before decreasing. 23 This corroborates our presented results of low or not detectable IL-6 serum levels measured at the first removal of dressing performed within 48 to 96 hours post-injury.
In contrast to serum concentrations, however, we found IL-6 levels in wound fluids to be constantly elevated in all patients treated with VAC™ or Epigard™, indicating ongoing local inflammation independent from the type of dressing.
Similar to IL-6, FGF-2 levels did not differ in wound fluids of patients treated with VAC™ or Epigard™ and thus, indicating releasing mechanisms other than provoked by VAC™ therapy. Trengove et al. postulated that the highly proteolytic extracellular environment of chronic wounds may have direct effects on the levels of FGF, which is a matrix bound growth factor. 24 Interestingly, in the same study a direct relationship between IL-6 and FGF was found which could explain our findings of comparable FGF-2 levels in wound fluids during both VAC™ and Epigard™ treatment.
In contrast to IL-6 as well as FGF-2, significantly higher local IL-8 concentrations In severely ischemic and/or hypoxic wound conditions, increasing oxygen concentrations result in accelerated wound healing with increased blood vessel growth. 28, 29 In vitro studies demonstrated that hyperbaric oxygen leads to upregulation of platelet derived growth factor (PDGF) receptor in the presence of oxidants such as hydrogen peroxide, stimulating endothelial cells and keratinocytes to release VEGF. 30, 31 Similarly, an experimental wound model in rats showed increased VEGF levels of approximately 40% under hyperbaric oxygen therapy. 32 In addition, clinical and experimental studies have shown that mechanical stretch triggers VEGF secretion. [33] [34] [35] Taken together, this supports our clinical findings of significantly higher VEGF levels in wound fluids during VAC™ therapy compared with Epigard™ application. Recent studies have demonstrated PMN and neutrophils in particular to express VEGF. 11, 12 Thus, the elevated local VEGF in wound fluids during VAC™ therapy in our study can be explained by increased and early accumulation of neutrophils as shown histologically. Elevated levels of VEGF were also demonstrated in our previous investigation where cytokines were measured in wound fluids of patients with traumatic wounds treated initially with Epigard followed by VAC therapy. 18 These results prompted us to assess the initial impact of VAC versus Epigard treatment on cytokine levels in wound fluids and local early inflammation. In addition to PMN, macrophages are known to be a source of VEGF peaking around the fifth day after injury in wound infiltration. 36 Interestingly, a more recent study also described an autocrine amplification mechanism for VEGF that induces chemotaxis of human neutrophils in extravascular tissue. 37 Finally, supported by our findings in wound biopsies of increased VEGF expression in PMN and presence of augmented small vessels during VAC™ treatment, it can be hypothesized that VAC™ therapy triggers neovascularization in traumatic soft tissue wounds.
The application of VAC™ as temporary wound coverage not only supports wound conditioning and facilitates definitive wound closure but also decreases frequency of dressing changes and risk of wound infection, offering considerable advantages regarding patient's comfort and hospital hygiene. 2 VAC therapy has been described to be beneficial for the wound management in a variety of complex soft tissue conditions such as destruction of chest wall musculature from trauma, empyema of local infection as well as infected war time missile injuries. 27, 38, 39 In contrast, our study could not reveal any significant difference regarding time point of definitive wound closure as well as hospital stay between patients receiving VAC™ therapy and patients treated with Epigard™. However, closure time as well 16 as hospital stay in particular are influenced by a variety of medical and non medical factors in these patients, and therefore, might not directly reflect advantages or disadvantages of any particular wound dressing. Thus, it can be hypothesized that the apparent positive effects of VAC therapy could be more accentuated in the treatment of other patients with more complex soft tissue wounds and therefore, additional clinical studies are necessary to further establish VAC™ therapy as a wound care modality.
These are the first data to demonstrate a selective and locally amplified humoral and cellular immune reaction as well as accelerated neovascularization during VAC™ therapy of traumatic soft tissue wounds compared with alternative Epigard™ application. However, further investigations are necessary in order to fully elucidate the exact mechanisms and kinetics of the wound healing process during VAC™ therapy. Table 2 , 72 hours after initial VAC application) or Epigard™ (E, F, G and H, patient number 25 in Table 3 Low expression of VEGF, x300.
